Depression can become especially exhausting when you have done what you were asked to do. You have taken medication consistently. You may have tried therapy, adjusted doses, changed prescribers, and waited through difficult weeks for a shift that never quite arrived.
At Revitalize Ketamine Clinic, we understand that treatment-resistant depression is not a personal failure or a lack of effort. It is a clinical reality that deserves careful attention. Definitions vary somewhat, but treatment resistance is often considered when adequate trials of more than one antidepressant have not brought sufficient improvement, a complexity described in clinical approaches to treatment-resistant depression (Kverno et al., 2021).
For eligible adults, SPRAVATO® is one option we offer for treatment-resistant depression. It is not a medication you simply pick up, take at home, and move on from. Its structure is deliberately supervised. That distinction matters.
What SPRAVATO® Is, and What It Is Not
SPRAVATO® is a prescription nasal spray containing esketamine, a form of ketamine. It is used alongside an oral antidepressant for adults with treatment-resistant depression. While ketamine-based treatments share some pharmacologic roots, they are not interchangeable services.
For example, our ketamine for depression treatment may involve a different clinical format than SPRAVATO®. IV ketamine for psychiatric uses is off-label, while SPRAVATO® is an FDA-approved prescription medication with specific administration and monitoring requirements.
Esketamine is understood to work differently from traditional antidepressants. Rather than acting primarily through serotonin or norepinephrine systems, it affects glutamate signaling, which is involved in communication between brain cells. The science is still evolving, but expert evidence reviews of ketamine and esketamine describe a distinct and clinically important treatment pathway for people whose depression has persisted despite standard care (McIntyre et al., 2021).
This does not mean it is right for everyone. Our role is to look carefully at your history, current medications, symptoms, medical considerations, and goals before deciding whether SPRAVATO® belongs in your care plan.
Why the Nasal Spray Is Given in a Clinic
SPRAVATO® is administered in a certified treatment setting under clinician supervision. You self-administer the nasal spray while our team is present, then remain with us for observation. The visit has a slower rhythm than a typical medication appointment. That is intentional.
After dosing, some people experience sleepiness, dizziness, nausea, changes in perception, or a detached or dreamlike feeling. These effects are usually temporary, but they deserve a calm environment and trained clinical attention. Research summaries of esketamine note the importance of supervised administration and post-dose observation (Jalloh, 2020).
Monitoring commonly includes:
Checking blood pressure before and after dosing
Watching for sedation, dissociation, or physical discomfort
Giving you quiet time to rest and reorient
Confirming that you have safe transportation home
Reviewing how you are feeling before you leave
You should not drive or operate machinery until the following day after restful sleep. A friend, family member, or other trusted adult should plan to take you home. This is one reason the treatment requires coordination, especially for families already carrying a great deal.
What We Emphasize During Treatment
We do not see monitoring as an administrative step. We see it as part of the care itself.
Depression can make the world feel narrowed, urgent, and lonely. A treatment visit should not add unnecessary confusion. We explain the day before it arrives, prepare you for possible sensations, check in with you directly, and make room for questions. If anxiety rises during observation, our staff is there.
We also pay attention to the larger picture. Medication may be one part of treatment, but sleep, support systems, therapy, substance use, stress, physical health, and past medication experiences all matter. Our depression treatment evaluation is designed to begin with that fuller conversation.
For some patients, ongoing psychiatric medication management remains an important part of stability. For others, we may discuss other services separately, including whether TMS treatment is effective for their individual circumstances. A thoughtful plan does not force every person into the same path.
What the Evidence Can, and Cannot, Tell You
The evidence for SPRAVATO® is meaningful, but it should be discussed honestly. In a randomized study, esketamine nasal spray combined with a newly initiated oral antidepressant showed greater improvement in depressive symptoms than an oral antidepressant plus placebo nasal spray for adults with treatment-resistant depression, as reported in this controlled clinical trial (Popova et al., 2019).
Longer-term care matters, too. In a relapse-prevention trial, continuing esketamine with an oral antidepressant reduced the risk of relapse among participants who had achieved stable response or remission during an earlier treatment phase, according to research on relapse prevention (Daly et al., 2019).
More recent comparative research also found that esketamine plus an antidepressant was more effective than quetiapine extended release plus an antidepressant for remission in a treatment-resistant depression population, as shown in a head-to-head trial (Reif et al., 2023).
Those findings are encouraging. They are not a prediction for any one person. Response can differ in timing, degree, tolerability, and durability. We will talk with you plainly about what improvement might look like, how progress is tracked, and when a plan may need adjustment.
A Sedona-Area Option With Northern Arizona Continuity
Patients come to us from Sedona, Flagstaff, Prescott Valley, and surrounding communities because persistent depression often requires more than another rushed appointment. Whether you are beginning in Sedona or seeking care in Flagstaff, we aim to make the process clear and clinically grounded.
We also recognize that families often need information before they can offer practical support. Bringing a loved one to an initial consultation can be helpful when appropriate. They may have questions about transportation, scheduling, monitoring, or what changes to watch for between visits.
Our Northern Arizona clinic can help you understand the available options and determine whether a SPRAVATO® evaluation is appropriate. We may also discuss how our IV ketamine care in Sedona differs from SPRAVATO®, so there is no confusion about the format, oversight, or clinical purpose of each service.
Frequently Asked Questions
Is SPRAVATO® the same as IV ketamine?
No. Both involve ketamine-related compounds, but SPRAVATO® is esketamine nasal spray administered in a supervised setting under its own prescribing and monitoring requirements. IV ketamine is a separate service, and psychiatric IV ketamine use is off-label.
How long will I be at the clinic?
Plan for the dosing visit and at least two hours of observation afterward. Your exact schedule, including the frequency of visits, depends on your prescribed treatment plan.
Can I take SPRAVATO® at home?
No. SPRAVATO® is administered under supervision at a certified treatment center. You will need transportation home after each visit.
What if I feel worse or have suicidal thoughts?
Tell us immediately, even if the feeling seems difficult to explain. If you are in immediate danger, call 911 or go to the nearest emergency department. You can also call or text the 988 Suicide and Crisis Lifeline at any time.
Key Takeaways
SPRAVATO® offers a supervised medication option for eligible adults with treatment-resistant depression. The nasal spray is only one part of the experience. Observation, blood-pressure checks, transportation planning, and ongoing clinical conversation are part of the treatment model as well.
If depression has remained present despite previous treatment, we invite you to reach out for a consultation. At our Flagstaff location, call 928-589-0567. For Sedona, call 928-325-2323. We will take the time to discuss your history, your questions, and whether SPRAVATO® care may be a reasonable next step.
Works Cited
1. Kverno KS, et al. Treatment-Resistant Depression: Approaches to Treatment. https://pubmed.ncbi.nlm.nih.gov/34459676/
2. McIntyre RS, et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. https://pubmed.ncbi.nlm.nih.gov/33726522/
3. Popova V, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. https://pubmed.ncbi.nlm.nih.gov/31109201/
4. Daly EJ, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/31166571/
5. Reif A, et al. Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. https://pubmed.ncbi.nlm.nih.gov/37792613/
6. Jalloh M. Esketamine (SPRAVATO®) for Treatment-Resistant Depression. https://pubmed.ncbi.nlm.nih.gov/32163257/
7. 988 Suicide and Crisis Lifeline. https://988lifeline.org/
Disclaimer
This article is for educational purposes only and is not a substitute for individualized evaluation, diagnosis, or treatment from a qualified healthcare professional.